Les chaperons pharmacologiques
- 1 June 2013
- journal article
- Published by EDP Sciences in médecine/sciences
- Vol. 29 (6-7) , 579-582
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studiesOrphanet Journal of Rare Diseases, 2012
- The Molecular Basis of Pharmacological Chaperoning in Human α-GalactosidaseChemistry & Biology, 2011
- A pharmacogenetic approach to identify mutant forms of α‐galactosidase a that respond to a pharmacological chaperone for Fabry diseaseHuman Mutation, 2011
- Chaperons pharmacologiquesmédecine/sciences, 2010
- Fabry diseaseOrphanet Journal of Rare Diseases, 2010
- Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probeInt. Journal of Clinical Pharmacology and Therapeutics, 2009
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseNew England Journal of Medicine, 2001
- Enzyme Replacement Therapy in Fabry DiseaseJAMA, 2001
- Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitorNature Medicine, 1999